As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

Sanofi plans to invest $20 billion in U.S.-based drug R&D and manufacturing over five years, creating jobs and boosting ...

Mersana Therapeutics restructures to focus on breast cancer, extends cash runway to mid-2026, and reports promising Emi-Le progress in TNBC.

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Roche warned that President Trump's executive order on drug pricing threatens its planned $50 billion investment in the ...

This cash-strapped company is shifting from its roots in cancer drug development to focus on cosmetic treatments.

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Press Release Top decision-makers from across the biopharma ecosystem will convene in Chicago for the 2nd BioCentury Grand Rounds – U.S., at the intersection of research, investment and drug ...

Recursion Pharmaceuticals faces a 57% stock drop amid drug setbacks, rising cash burn, and AI discovery doubts. Learn more ...